Prognostic value of non-cytotoxic HLA-antibodies for kidney transplantation

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00009229

Enrollment

5000

Registered

2015-08-13

Start date

2016-04-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N18.4 N18.5

Interventions

Group 1: Patients without pretransplant donor-specific HLA-antibodies (preTx-DSA) Group 2: Patients with weak preTx-DSA (less than 3000 MFI) Group 3: Patients with strong preTx-DSA (3000 MFI or more)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Kidney transplantation

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Incidence of antibody-mediated rejection during the first 6 months post transplantation	—

Secondary

Measure	Time frame
1) Death-censored transplant survival 2) Patient survival 3) Creatinine-value 4) Glomerular filtration rate 5) Intensity of immunosuppression 6) Incidence of delayed graft function (Time points: at hospital discharge, 6 months post transplantation, 1 year and yearly post transplantation)	—

Countries

Germany

Contacts

Public ContactMalte Ziemann

Institut für Transfusionsmedizin Universitätsklinikum Schleswig-Holstein

Malte.Ziemann@uksh.de0451-500-16001

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026